Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: April 27, 2007
Event: Entry into a Material Definitive Agreement with CyberHeart, Inc.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the execution of a strategic agreement.
Material Changes
On April 27, 2007, Accuray executed a License and Development Agreement with CyberHeart, Inc. Key terms include:
- Licensing: Accuray licenses intellectual property and technologies to CyberHeart for the development of cardiac disease systems.
- Supply Arrangement: Accuray will be the sole supplier of radiosurgery equipment to CyberHeart if the application is successfully commercialized.
- Compensation: Accuray is entitled to specified payments based on the usage of the CyberHeart system.
- Duration: The agreement remains in effect until the last of certain specified Accuray patents expires, unless terminated earlier.
Outlook, Risks, and Contingencies
Management Commentary: The agreement aims to expand Accuray's technology into the cardiac disease field. The full text of the agreement will be filed as an exhibit to the Annual Report on Form 10-K for the year ended June 30, 2007, with certain terms seeking confidential treatment.
Contingencies: Future payments and the sole supplier status are contingent upon CyberHeart's successful development and commercialization of the new application.
Investor Verification Checklist
- Verify the specific payment terms and usage metrics once the agreement is filed as an exhibit to the Form 10-K.
- Monitor CyberHeart's progress in developing and commercializing the cardiac disease application.
- Review the list of specific patents covered by the agreement to understand the duration of the contract.
- Assess the potential impact of this partnership on Accuray's future revenue streams in the cardiac sector.